A PYMNTS Company

U.S.: FTC pulls antitrust probe over Yasmin deals

By  |  October 4, 2012

According to the FTC, the Bayer Schering Pharma AG and Barr Laboratories Inc. settlements, which relate to patent infringement allegations over Bayer’s Yasmin birth control drug, will no longer be subject to antitrust scrutiny. The FTC is also closing an investigation into the deals that aimed to monitor competititve behavior.

Full Content: Law360

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.